Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Next Previous
Trial Profile

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Musculoskeletal pain; Rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 01 Dec 2015 Primary endpoint (change in average pain intensity, assessed by the brief pain inventory short form) has not been met according to the results published in The Journal of Rheumatology.
  • 01 Dec 2015 Results published in The Journal of Rheumatology
  • 25 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top